International Companies

Novo Nordisk slashes US prices for Wegovy, Ozempic as competition ramps up

By Benjamin Chiou

Date: Tuesday 24 Feb 2026

(Sharecast News) - Danish pharma giant Novo Nordisk is to halve the US price of obesity drug Wegovy and slash the price of diabetes treatment Ozempic from next year as competition ramps up with rival drugmaker Eli Lilly.
From 1 January 2027, both Wegovy and Ozempic will have list prices of...

Sign up for free or to read the full story

Email this article to a friend

or share it with one of these popular networks:


Article Archive

Top of Page